Piper Sandler downgraded Verona Pharma (VRNA) to Neutral from Overweight with a price target of $107, down from $160, after Merck (MRK) announced it will acquire Verona for $10B or $107 per share.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA: